This suggests that mRNA-based thresholds for identifying PD-L1+ paediatric tumours may not reliably identify tumours which are PD-L1+ by IHC criteria, and PD-L1 TPM-based criteria in clinical trials of checkpoint inhibition require further validation. The gene discussed is CD274; the disease is neoplasm.